Gamma-hydroxybutyric Acid (GHB), Urine
Gamma-hydroxybutyric acid (GHB) is a hydroxylated, short-chain fatty acid. GHB was first introduced in Europe in the 1960s as an intravenous general anesthetic agent that lacked analgesic properties. The main therapeutic effects of GHB appear to be its ability to suppress the symptoms of alcohol dependence and opiate-withdrawal syndrome, and for the management of narcoleptic patients. Another effect of GHB is that it can act as a very strong sedative and induce amnesia in individuals. GHB has been implicated in a number of drug-facilitated sexual assault cases (DSFA). GHB abuse has also been linked to bodybuilders. Bodybuilder’s abuse is based on the fact that GHB tends to build body mass similar to steroidal use by increasing the release of human growth hormone.
GHB and its analogs are drugs that sexual predators tend to use, not only for the effect they produce in individuals but also because statistically it is hard to prove that a person was under the influence. This is due to the fact that GHB is naturally present in the body, so evaluating its role in cases of suspected DFSA can be complicated. In addition, GHB is rapidly eliminated after ingestion leaving only very low concentrations of GHB behind to be detected.
Low doses of GHB (approximately 0.5-1.5g) induce a state of relaxation and tranquility, placidity, sensuality, mild euphoria, a tendency to verbalize, emotional warmth, and drowsiness. Individuals that take higher doses (1.5 grams or more) can experience adverse effects, such as confusion, dizziness, and drowsiness, nausea and vomiting, agitation, nystagmus, loss of peripheral vision, hallucinations, short-term amnesia, somnolence, uncontrollable shaking, or seizures, combativeness, bradycardia, respiratory depression, apnea, and coma. GHB is usually taken orally as a solution and is rapidly absorbed and metabolized, producing plasma concentrations peaking within 30 minutes and urinary concentrations peaking in about 1 hour. GHB is lipid soluble, which allows it to readily pass the blood-brain barrier where it exerts its therapeutic effect. GHB is not extensively bound to protein. The primary pathway of metabolism is via the Krebs cycle, since GHB is metabolized to succinic semialdehyde before being converted to succinic acid.
Analytical methods employed to detect GHB in serum and urine include Gas Chromatography/Mass Spectroscopy (GC/MS) and Liquid Chromatography/Mass Spectroscopy (LC/MS).
- Therapeutic monitoring in serum
- Drug abuse evaluation
- Toxicity assessment in serum
- DFSA assessment
Wakefulness:
- Drowsiness/Light sleep: 50 - 150 µg/mL
- Moderate sleep: 150 - 260 µg/mL
- Deep sleep: >260 µg/mL
Note: therapeutic ranges and toxic thresholds are best evaluated from blood samples. Quantitative results obtained with blood samples collected at specific times after drug administration are preferred for pharmacokinetic analyses.
Cut-Off Ranges
Cut-off values are used to determine the positivity of the urine specimen being analyzed. Cut-off values can vary based on the particular method of analysis that is used for detection whether it is LC/MS or GC/MS. The testing laboratory cut-off range is listed on the patient report. Consult your physician for further information or click on one of the references that are listed below.
First catch urine specimen collected in either a clean glass or plastic container. An acceptable urine specimen submitted for testing should be in the pH range of 3-11. Adulteration of the urine specimen can result in erroneous results.
Stability
- If not analyzed quickly, urine or blood samples should be frozen at -20 °C.
- J Clin Pharmacol. 2004;44:253-7. [PMID: 14973300]
- J Anal Toxicol. 2012;36:88-95. [PMID: 22337777]
- J Anal Toxicol. 2004;28:625-30. [PMID: 15538955]
- J Anal Toxicol. 2004;28:20-6. [PMID: 14987420]
- J Pharm Pharmacol. 2001;53:399-402. [PMID: 11291756]
- Ana Toxicol. 2002;26:340-6. [PMID: 12220015]
- J Anal Toxicol. 1999;23:301-5. [PMID: 10488915]